Elsevier

Biochemical Pharmacology

Volume 47, Issue 2, 20 January 1994, Pages 317-329
Biochemical Pharmacology

Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells

https://doi.org/10.1016/0006-2952(94)90023-XGet rights and content

Abstract

In the MCF-7 human breast tumor cell line, the aminoacridine, m-AMSA, induces protein-associated DNA strand breaks consistent with inhibition of topoisomerase II. However, neither single-strand nor double-strand breaks in DNA, determined using conventional assays, show a consistent relationship with m-AMSA-induced inhibition of growth. In contrast, when DNA strand breaks are determined by alkaline unwinding under the high salt conditions of the alkaline unwinding/Southern blotting (AU/SB) assay, developed by our laboratories, damage to DNA corresponds closely with growth inhibition. The AU/SB assay, which is capable of assessing breaks within large-scale domains (upwards of 1 megabase) surrounding genes of interest, was further utilized to explore the capacity of m-AMSA to induce damage within specific genomic regions that may regulate cell growth. Regions encompassing the transcriptionally active oncogenes, c-myc and c-fos, were found to be more susceptible to m-AMSA-induced strand breaks than the region encompassing the non-transcribed α-satellite DNA or the genome as a whole (bulk DNA). These findings demonstrate that m-AMSA may produce more pronounced damage within specific genomic regions than in bulk DNA. m-AMSA also preferentially altered expression of the c-myc oncogene; at an m-AMSA concentration where growth was inhibited by between 70 and 80%, steady-state c-myc mRNA levels declined to approximately 10–15% of control levels within 2–3 hr; furthermore, concentration-dependent reductions in c-myc expression appeared to coincide with growth inhibition. In addition, inhibition of [3H]thymidine incorporation after 2 hr directly paralleled inhibition of growth, suggesting an early effect at the level of DNA biosynthesis, possibly related to the down-regulation of c-myc expression. It is proposed that specific lesions, e.g., in regions surrounding the c-myc gene, as well as generalized lesions in DNA may lead to growth inhibition mediated by down-regulation of the expression of select growth regulatory genes, such as c-myc.

References (63)

  • S Osanto et al.

    Downmodulation of c-myc expression by interferon α and tumor necrosis factor α precedes growth arrest in human melanoma cells

    Eur J Cancer

    (1992)
  • M Kashani-Sabet et al.

    Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells

    J Biol Chem

    (1990)
  • EL Schwartz et al.

    Inhibition of c-myc expression in human promyelocytic leukemia and colon adenocarcinoma by 6-thioguanine

    Biochem Pharmacol

    (1990)
  • KM Tewey et al.

    Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II

    Science

    (1984)
  • N Osheroff

    Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: Inhibition of DNA religion by etoposide

    Biochemistry

    (1989)
  • Y Pommier et al.

    Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells

    Cancer Res

    (1985)
  • K-C Chow et al.

    Topoisomerase-specific drug sensitivity in relation to cell cycle progression

    Mol Cell Biol

    (1987)
  • J-F Riou et al.

    Stimulation of the topoisomerase II induced DNA cleavage sites in the c-myc protooncogene by antitumor drugs is associated with gene expression

    Biochemistry

    (1989)
  • J-F Riou et al.

    In vivo and in vitro stimulation by antitumor drugs of the topoisomerase II-induced cleavage sites in c-myc protooncogene

    NCI Monogr

    (1987)
  • Y Pommier et al.

    Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in human c-myc protooncogene

    Cancer Res

    (1992)
  • W Waitz et al.

    Cell cycle dependent association of c-myc protein with the nuclear matrix

    Oncogene

    (1991)
  • PH Watson et al.

    Inhibition of c-myc expression by phosphorothionate antisense oligo-nucleotide identifies a critical role for c-myc in the growth of human breast cancer

    Cancer Res

    (1991)
  • D Dubik et al.

    Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells

    Cancer Res

    (1987)
  • DA Gewirtz et al.

    Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line: Evidence for induction of gene-specific damage and alterations in gene expression

    Cancer Res

    (1993)
  • R Dalla Favera et al.

    onc Gene amplification in promyelocytic leukemia cell HL-60 and primary leukemic cells of the same patient

    Nature

    (1982)
  • C Munger et al.

    Evidence for inhibition of growth related to compromised DNA synthesis in the interaction of daunorubicin with H-35 rat hepatoma

    Cancer Res

    (1988)
  • J Carmichael et al.

    Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing

    Cancer Res

    (1987)
  • PM Kanter et al.

    A fluorescence enhancement assay for cellular DNA damage

    Mol Pharmacol

    (1982)
  • KW Kohn et al.

    Measurement of strand breaks and cross links by alkaline elution

  • DA Gewirtz et al.

    Expression of protein-associated DNA damage in the alkaline elution assay in the absence of enzymatic deproteinization

    Cancer Commun

    (1989)
  • RT Bunch et al.

    A combined alkaline unwinding/Southern blotting assay for measuring low levels of cellular DNA breakage within specific genomic regions

    Oncol Res

    (1992)
  • Cited by (29)

    • A cell competition–based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation

      2021, Journal of Biological Chemistry
      Citation Excerpt :

      Collectively, these data demonstrate that DJ34 is a DNA intercalator and a strong inhibitor of topo II, but not topo I. It has previously been shown that intron 1 of the c-MYC gene contains a sequence that reduces c-MYC transcription because of torsional tension that arises during transcription, and the activity of topo II is essential for relieving this tension and maintaining high levels of c-MYC transcription; indeed, expression of plasmid-encoded c-MYC complementary DNA lacking this intron does not require topo II activity (37–40). We analyzed c-Myc levels in the MIA–PaCa GPS–Myc cell line (41), which contains the endogenous WT c-MYC alleles in addition to a randomly integrated dsRED–IRES–GFP–c-MYC construct (Fig. 6G).

    • Induction of G<inf>2</inf>/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes

      2002, Biochemical Pharmacology
      Citation Excerpt :

      The refractoriness of MCF-7 cells to apoptosis induced by doxorubicin [12,34] or WP631 [9] and the limited apoptosis observed in Jurkat T cells after 72 hr treatment agrees with finding that the transcription of c-myc was highly sensitive to nanomolar concentrations of WP631 (Fig. 8). There is a known association between the effects of some drugs on c-myc expression and the response to DNA damage in MCF-7 cells [12,34]. We recently reported a diminution in c-myc RNA levels, without apoptosis, in MCF-7 cells as a result of WP631 treatment [9].

    • Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells

      2001, Biochemical Pharmacology
      Citation Excerpt :

      In agreement with this concept, c-Myc-induced pathways that regulate apoptosis and cell cycle progression can be separated pharmacologically by treating myeloid cells with cyclic AMP analogues [15]. Transient exposure of MCF-7 breast tumor cells to the topoisomerase II inhibitors VM-26, doxorubicin, and m-AMSA, or to ionizing radiation, produces an early concentration-dependent (and in the case of radiation, a dose-dependent) reduction in c-myc transcript levels [16–19]. Suppression of c-myc mRNA by VM-26 (as well as by ionizing radiation) is a transient effect [18,19], which may be related to the transient nature of DNA strand breaks induced by acute exposure to topoisomerase II inhibitors or ionizing radiation [20–23].

    View all citing articles on Scopus
    View full text